Alnylam Pharmaceuticals (BSP:A1LN34) Debt-to-Equity

: -5.92 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Alnylam Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$203 Mil. Alnylam Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$6,193 Mil. Alnylam Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was R$-1,081 Mil. Alnylam Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was -5.92.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Alnylam Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

BSP:A1LN34' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.34 Med: 0.09 Max: 1.7
Current: -5.92

During the past 13 years, the highest Debt-to-Equity Ratio of Alnylam Pharmaceuticals was 1.70. The lowest was -8.34. And the median was 0.09.

BSP:A1LN34's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs BSP:A1LN34: -5.92

Alnylam Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Alnylam Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.21

0.51

1.70

-8.34

-5.92

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																-8.34	-5.09	-3.22	-7.89	-5.92

Competitive Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Debt-to-Equity falls into.

Alnylam Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Alnylam Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(203.391	+	6192.745)	/	-1081.111
	=	-5.92

Alnylam Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(203.391	+	6192.745)	/	-1081.111
	=	-5.92

Alnylam Pharmaceuticals (BSP:A1LN34) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Alnylam Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines